Related Experiment Videos
Cholesterol supplementation does not improve developmental progress in Smith-Lemli-Opitz syndrome
Darryn M Sikora1, Mark Ruggiero, Kersti Petit-Kekel
1Departments of Pediatrics, Doernbecher Children's Hospital, Portland, Oregon, USA. sikorad@ohsu.edu
The Journal of Pediatrics
|June 12, 2004
Summary
Cholesterol supplementation did not improve developmental progress in children with Smith-Lemli-Opitz syndrome (SLOS). Baseline cholesterol levels were the best predictor of developmental outcomes in this 6-year study.
Area of Science:
- Biochemistry
- Genetics
- Pediatrics
Background:
- Smith-Lemli-Opitz syndrome (SLOS) is a genetic disorder characterized by malformations, growth deficiency, and intellectual disability.
- Cholesterol supplementation is a common treatment approach for managing SLOS symptoms.
Purpose of the Study:
- To assess the long-term (6-year) developmental progress of children and adolescents with SLOS receiving continuous cholesterol supplementation.
- To evaluate the impact of cholesterol supplementation on cognitive, motor, and adaptive skills in SLOS patients.
Main Methods:
- A longitudinal study involving 14 patients with SLOS receiving continuous cholesterol supplementation.
- Developmental assessments conducted every 6 to 12 months.
- Analysis using repeated-measures design and multiple t tests to evaluate progress over time.
Main Results:
- No significant improvement in developmental quotients was observed in children with SLOS during the 6-year study period.
- Baseline cholesterol levels, not the age of supplementation initiation or cholesterol level increase, were the strongest predictors of developmental outcomes.
- The current form of cholesterol supplementation did not enhance developmental progress.
Conclusions:
- Cholesterol supplementation, as currently administered, does not appear to improve developmental outcomes in individuals with SLOS.
- Further research may be needed to explore alternative or modified therapeutic strategies for SLOS.